Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.24
+0.42 (2.50%)
At close: Jul 24, 2026, 4:00 PM EDT
17.02
-0.22 (-1.25%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Takeda Pharmaceutical Revenue
In the fiscal year ending March 31, 2026, Takeda Pharmaceutical had annual revenue of 4.51T JPY, down -1.66%. Takeda Pharmaceutical had revenue of 1.09T in the quarter ending March 31, 2026, with 3.90% growth.
Revenue (ttm)
4.51T JPY
Revenue Growth
-1.66%
P/S Ratio
1.94
Revenue / Employee
95,806,843 JPY
Employees
47,029
Market Cap
55.09B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.85B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.42B | 8.63% |
| Mar 31, 2013 | 1.56T | 48.34B | 3.20% |
| Mar 31, 2012 | 1.51T | 89.55B | 6.31% |
| Mar 31, 2011 | 1.42T | -46.58B | -3.18% |
| Mar 31, 2010 | 1.47T | -72.37B | -4.70% |
| Mar 31, 2009 | 1.54T | 163.53B | 11.90% |
| Mar 31, 2008 | 1.37T | 69.64B | 5.34% |
| Mar 31, 2007 | 1.31T | 92.96B | 7.67% |
| Mar 31, 2006 | 1.21T | 89.25B | 7.95% |
| Mar 31, 2005 | 1.12T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.56B |
| Zoetis | 9.53B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.50B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
TAK News
- 4 days ago - Takeda dengue vaccine receives marketing authorization from India DCGI - TheFly
- 5 days ago - Takeda's QDENGA becomes first dengue vaccine approved in India - Reuters
- 9 days ago - Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies - Business Wire
- 12 days ago - Takeda Pharmaceutical (TAK) Launches Plasma Ecosystem Initiative in Indonesia - GuruFocus
- 12 days ago - Takeda, the Indoensian Government announce collaboration - TheFly
- 12 days ago - Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products - Business Wire
- 22 days ago - Takeda Pharmaceutical Co Ltd (TAK) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
- 23 days ago - Insilico Medicine Announces Strategic AI Drug Discovery Collaboration With Takeda - Nasdaq